Brown Advisory Inc. Takes $235,000 Position in CRISPR Therapeutics AG (NASDAQ:CRSP)

Brown Advisory Inc. acquired a new stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSPFree Report) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 3,755 shares of the company’s stock, valued at approximately $235,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Jump Financial LLC boosted its stake in shares of CRISPR Therapeutics by 194.7% during the third quarter. Jump Financial LLC now owns 33,307 shares of the company’s stock valued at $1,512,000 after purchasing an additional 22,006 shares in the last quarter. Invesco Ltd. boosted its stake in CRISPR Therapeutics by 1.5% in the third quarter. Invesco Ltd. now owns 136,123 shares of the company’s stock valued at $6,179,000 after acquiring an additional 2,061 shares in the last quarter. ARK Investment Management LLC boosted its stake in CRISPR Therapeutics by 19.2% in the fourth quarter. ARK Investment Management LLC now owns 8,536,104 shares of the company’s stock valued at $534,360,000 after acquiring an additional 1,372,986 shares in the last quarter. Prime Capital Investment Advisors LLC acquired a new stake in CRISPR Therapeutics in the fourth quarter valued at approximately $206,000. Finally, Baker Chad R boosted its stake in CRISPR Therapeutics by 89.1% in the fourth quarter. Baker Chad R now owns 98,520 shares of the company’s stock valued at $6,167,000 after acquiring an additional 46,420 shares in the last quarter. 69.20% of the stock is currently owned by institutional investors.

Insider Buying and Selling at CRISPR Therapeutics

In other CRISPR Therapeutics news, General Counsel James R. Kasinger sold 2,801 shares of CRISPR Therapeutics stock in a transaction on Monday, March 11th. The shares were sold at an average price of $78.26, for a total value of $219,206.26. Following the completion of the transaction, the general counsel now owns 60,070 shares of the company’s stock, valued at $4,701,078.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, CFO Raju Prasad sold 3,524 shares of CRISPR Therapeutics stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $72.69, for a total value of $256,159.56. Following the sale, the chief financial officer now owns 6,476 shares in the company, valued at $470,740.44. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, General Counsel James R. Kasinger sold 2,801 shares of CRISPR Therapeutics stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $78.26, for a total transaction of $219,206.26. Following the completion of the sale, the general counsel now owns 60,070 shares in the company, valued at approximately $4,701,078.20. The disclosure for this sale can be found here. Over the last quarter, insiders sold 55,709 shares of company stock valued at $3,865,228. Corporate insiders own 4.10% of the company’s stock.

Analyst Ratings Changes

CRSP has been the subject of several recent analyst reports. Wells Fargo & Company lowered their target price on shares of CRISPR Therapeutics from $70.00 to $65.00 and set an “equal weight” rating for the company in a research note on Thursday, May 9th. Mizuho raised their price target on shares of CRISPR Therapeutics from $82.00 to $99.00 and gave the stock a “buy” rating in a report on Wednesday, March 6th. Royal Bank of Canada raised their price target on shares of CRISPR Therapeutics from $57.00 to $66.00 and gave the stock a “sector perform” rating in a report on Thursday, February 22nd. Barclays decreased their price target on shares of CRISPR Therapeutics from $80.00 to $67.00 and set an “equal weight” rating for the company in a report on Thursday, May 9th. Finally, Oppenheimer decreased their price target on shares of CRISPR Therapeutics from $102.00 to $95.00 and set an “outperform” rating for the company in a report on Friday, May 10th. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $73.57.

Get Our Latest Report on CRISPR Therapeutics

CRISPR Therapeutics Stock Performance

CRSP opened at $55.24 on Tuesday. CRISPR Therapeutics AG has a fifty-two week low of $37.55 and a fifty-two week high of $91.10. The company has a fifty day moving average of $60.23 and a two-hundred day moving average of $65.66. The stock has a market capitalization of $4.69 billion, a price-to-earnings ratio of -20.31 and a beta of 1.80.

CRISPR Therapeutics (NASDAQ:CRSPGet Free Report) last released its quarterly earnings data on Wednesday, May 8th. The company reported ($1.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.08). The business had revenue of $0.50 million for the quarter, compared to the consensus estimate of $25.53 million. During the same period last year, the firm earned ($0.67) earnings per share. The business’s quarterly revenue was down 99.5% compared to the same quarter last year. On average, equities research analysts forecast that CRISPR Therapeutics AG will post -5.64 earnings per share for the current year.

CRISPR Therapeutics Company Profile

(Free Report)

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

Featured Articles

Institutional Ownership by Quarter for CRISPR Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.